Skandinaviska Enskilda Banken AB publ Has $167.77 Million Holdings in Bristol Myers Squibb Company $BMY

Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 59.9% in the third quarter, HoldingsChannel reports. The firm owned 3,719,987 shares of the biopharmaceutical company’s stock after acquiring an additional 1,393,646 shares during the period. Bristol Myers Squibb makes up 0.7% of Skandinaviska Enskilda Banken AB publ’s portfolio, making the stock its 24th biggest position. Skandinaviska Enskilda Banken AB publ’s holdings in Bristol Myers Squibb were worth $167,771,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in shares of Bristol Myers Squibb by 0.5% in the third quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock valued at $8,838,879,000 after buying an additional 1,058,803 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Bristol Myers Squibb by 16.8% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after acquiring an additional 10,195,775 shares during the last quarter. Geode Capital Management LLC increased its position in Bristol Myers Squibb by 1.6% in the 2nd quarter. Geode Capital Management LLC now owns 46,176,690 shares of the biopharmaceutical company’s stock valued at $2,132,976,000 after acquiring an additional 723,459 shares in the last quarter. Norges Bank bought a new position in shares of Bristol Myers Squibb in the second quarter worth about $1,554,154,000. Finally, Ameriprise Financial Inc. lifted its position in shares of Bristol Myers Squibb by 1.3% during the second quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock worth $1,508,099,000 after purchasing an additional 432,158 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $60.64 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The firm has a market capitalization of $123.49 billion, a P/E ratio of 17.58, a PEG ratio of 0.17 and a beta of 0.29. The business has a 50-day moving average of $55.50 and a 200-day moving average of $49.61. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same quarter in the prior year, the firm posted $1.67 EPS. The firm’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BMY. Scotiabank reissued a “sector perform” rating and issued a $60.00 price target (up previously from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their price target for the company from $52.00 to $61.00 in a research note on Monday, December 15th. Piper Sandler reiterated an “overweight” rating and issued a $66.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a research report on Wednesday, January 28th. Finally, Citigroup upped their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Eight research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $59.20.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.